4.7 based on 2,000 reviews

Tirzepatide (GLP-2)

Tirzepatide (GLP-2)

$169.00
$169.00
SAVE Sold out
Tirzepatide (GLP-2)

Tirzepatide (GLP-2)

$169.00
$169.00
SAVE Sold out

Tirzepatide (GLP-2) is a once-weekly injectable medication developed by Eli Lilly for the treatment of type 2 diabetes (T2DM) and obesity. It is the first dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonist, designed to enhance glycemic control and induce significant weight loss. Its dual action makes it more effective than traditional GLP-1 therapies, offering promise in both metabolic and cardiovascular health domains.

check_box

Applications

  • Type 2 diabetes mellitus (T2DM) management
  • Chronic weight management for obesity or overweight individuals with comorbidities
  • Prediabetes intervention and diabetes prevention
  • Cardiometabolic support in heart failure with preserved ejection fraction (HFpEF)
check_box

Mechanism of Action

GLP-1 Receptor Agonism: Amplifies insulin response to glucose and influences lipid metabolism and adipose tissue regulation
No Impact on Blood Sugar: Does not affect insulin levels or glucose metabolism
Dual Incretin Effect: Combines GLP-1 and GIP signaling pathways to synergistically improve glycemic control and promote weight loss

check_box

Key Research Studies

1. Weight Loss Efficacy

  • Study: SURMOUNT-1
  • Findings: Up to 22.9% average body weight reduction over 3 years in people with prediabetes and obesity
  • Reference: ​Verywell Health+2Reuters+2Time+2

2. Weight Loss After Lifestyle Intervention

3. Head-to-Head Comparison with Semaglutide

  • Finding: Tirzepatide resulted in greater weight loss (20.2%) than semaglutide (13.7%)
  • Reference: ​Lilly Investor Relations

4. Diabetes Prevention

5. Cardiovascular Benefits (HFpEF)

6. Glycemic Control Superiority

  • Study: Compared to Semaglutide
  • Finding: Tirzepatide was both noninferior and superior in reducing HbA1c over 40 weeks
  • Reference: ​New England Journal of Medicine
View full details

Biological Effects and Benefits

check_circle
Weight Loss:

Superior and sustained reductions in body weight compared to other incretin-based therapies

check_circle
Blood Sugar Regulation:

Improves insulin sensitivity, reduces HbA1c, and promotes glucose homeostasis

check_circle
Diabetes Prevention:

Dramatically lowers the risk of T2DM progression in prediabetic patients

check_circle
Cardiovascular Health:

Reduces heart failure outcomes and improves cardiometabolic parameters

check_circle
Lipid and Appetite Regulation:

GIP component may aid lipid metabolism and appetite control beyond GLP-1 effects

  • Peptide Sequence: Not specified in the document

  • Molecular Formula: Not specified in the document

  • Molecular Weight: Not specified in the document

  • Notes: Tirzepatide is a synthetic peptide that combines agonist activity at both the GIP and GLP-1 receptors for enhanced therapeutic effects

Molecular Structure